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BACKGROUND Innate immune responses activated through myeloid cells contribute to the 
initiation, progression, and complications of atherosclerosis in experimental models. However, 
the critical upstream pathways that link innate immune activation to foam cell formation are still 
poorly identified.  
OBJECTIVES We hypothesized that activation of the triggering receptor expressed on myeloid 
cells (TREM-1) plays a determinant role in macrophage atherogenic responses. 
METHODS After genetically invalidating Trem-1 in chimeric Ldlr-/- Trem-1-/- mice and double 
knockout Apoe-/- Trem-1-/- mice, we pharmacologically inhibited Trem-1 using LR12 peptide. 
RESULTS Ldlr-/- mice reconstituted with bone marrow deficient for Trem-1 (Trem-1-/-) showed 
a strong reduction of atherosclerotic plaque size in both the aortic sinus and the thoraco-
abdominal aorta, and were less inflammatory compared to plaques of Trem-1+/+ chimeric mice. 
Genetic invalidation of Trem-1 led to alteration of monocyte recruitment into atherosclerotic 
lesions and inhibited toll-like receptor (TLR) 4-initiated pro-inflammatory macrophage 
responses. We identified a critical role for Trem-1 in the upregulation of cluster of differentiation 
(CD) 36, thereby promoting the formation of inflammatory foam cells. Genetic invalidation of 
Trem-1 in Apoe-/-/Trem-1-/- mice or pharmacological blockade of Trem-1 in Apoe-/- mice using 
LR-12 peptide also significantly reduced the development of atherosclerosis throughout the 
vascular tree, and lessened plaque inflammation. TREM-1 was expressed in human 
atherosclerotic lesions mainly in lipid-rich areas, with significantly higher levels of expression in 
atheromatous compared to fibrous plaques. 
CONCLUSION We identify TREM-1 as a major upstream pro-atherogenic receptor. We 
propose that TREM-1 activation orchestrates monocyte/macrophage pro-inflammatory responses 
and foam cell formation through coordinated and combined activation of CD36 and TLR4. 
Blockade of TREM-1 signaling may constitute an attractive novel and double-hit approach for 
the treatment of atherosclerosis. 
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ABBREVIATIONS AND ACRONYMS 
Apo = apolipoprotein 
CD = cluster of differentiation 
IL = interleukin 
LDL = low density lipoprotein 
SMC = smooth muscle cell 
TLR = toll-like receptor 
TREM = triggering receptors expressed on myeloid cells 
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Ischemic cardiovascular diseases, largely due to atherosclerosis, are expected to remain 
the main cause of death globally for the next 15 years, forcing us to revisit their basic 
mechanisms and consider new strategies for prevention and treatment (1-3). There is a large 
body of human and experimental evidence indicating that innate immune cells, particularly 
monocytes/macrophages, are involved in the initiation and progression of atherosclerosis and its 
complications, such as plaque rupture and consecutive acute myocardial infarction (AMI) (4,5). 
Activation of the vascular wall after subendothelial retention and modification of apolipoprotein 
(Apo) B containing low-density lipoproteins (LDL) promotes the recruitment of circulating 
monocytes into the intima. Accumulating monocytes significantly contribute to the pool of 
macrophages in lesions (6). Monocytes differentiate into macrophages and lipid-laden foam 
cells, and promote plaque development and vulnerability through cytokine, chemokine, and 
matrix metalloprotease production and through direct interactions with surrounding 
inflammatory and vascular cells. Macrophage differentiation, activation, and proliferation are 
necessary steps for atherosclerosis and are associated with upregulation of pattern recognition 
receptors for innate immunity, including scavenger receptors (SR-A, cluster of differentiation 
[CD] 36) and toll-like receptors (TLR) (7-9). Macrophages internalize and are activated by a 
broad range of molecules and particles bearing danger-associated molecular patterns (e.g., 
oxidized LDL, apoptotic debris) and ultimately are transformed into pro-inflammatory foam 
cells. However, the critical upstream pathways that link inflammatory cell activation and foam 
cell formation and lead to the generation of pro-inflammatory lipid-laden macrophages are still 
poorly defined. Direct interactions between scavenger receptors involved in lipid body formation 
(e.g., CD36), and TLR involved in the induction of inflammatory responses (e.g., TLR2, TLR4, 
TLR6) have been identified (10,11) and proposed to play a role in this process (11). However, 
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the independent in vivo impact of such pathways on lesion development and the accumulation of 
pro-inflammatory foamy macrophages remain modest. For example, deletion of CD36 does not 
limit lesion development in low-density lipoprotein receptor (Ldlr)-/- mice (12) and reduced 
atherosclerosis only in the descending aorta of Apoe-/- mice (13). Moreover, lesion development 
was not significantly altered in Ldlr-/- mice despite combined deficiency of TLR2 and TLR4 in 
macrophages (10). Thus, the critical receptor, or combination of receptors, that play 
nonredundant roles in orchestrating the development of pro-inflammatory foamy macrophages 
are still to be defined. 
Triggering receptors expressed on myeloid cells (TREM) proteins are a family of cell 
surface receptors, members of the immunoglobulin family, discovered 15 years ago by Bouchon 
(14,15). TREM-1 expression is constitutive on neutrophils and monocytes/macrophages and 
increases in response to lipopolysaccharide or other microbial products (15). Engagement of 
TREMs, after association with the adapter protein DAP12, has been shown to stimulate the 
production of pro-inflammatory cytokines and chemokines, such as interleukin (IL)-8, CCL-2, 
and CCL-7, as well as stimulating rapid neutrophil degranulation. Activation of TREM-1 in the 
presence of TLR2 or TLR4 ligands amplifies the production of pro-inflammatory cytokines 
(tumor necrosis factor [TNF]-α, IL-1β) while inhibiting the release of anti-inflammatory IL-10 
(16). TREM-1 also regulates monocyte and neutrophil migration to inflammatory sites (15,17). 
TREM-1 has been mainly studied during septic shock, but it also is critical during aseptic 
inflammation, both acute (pancreatitis) (18) and chronic (rheumatoid arthritis) (19). A recently 
designed dodecapeptide named LR12 (LQEEDAGEYGCM), derived from TREM-1-like 
transcript 1, strongly inhibits TREM-1 engagement by competing with its still unknown 
endogenous ligand. LR12 modulates the innate immune response following bacterial aggression 
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in rodents (20), pigs (21), and primates (22), translating into an attenuation of organ dysfunction 
and improved outcome (20,21). We recently reported that TREM-1 is involved is post-ischemic 
myocardial remodeling by orchestrating leukocyte recruitment to the ischemic heart and 
subsequent inflammatory responses (23). Additionally, in a multicenter cohort of patients with 
acute coronary syndromes, we showed that plasma TREM-1 level was an independent predictor 
of major adverse cardiovascular events (23). 
Here, we evaluated the effects of TREM-1 in murine monocytes/macrophages on 
inflammatory cell activation, trafficking, and foam cell formation to assess TREM-1 as an 
upstream target in atherosclerosis. 
Methods 
Human Carotid Plaques 
The processing and examination of the dissected atherosclerotic plaques have been 
previously described (24). All stainings were examined microscopically and plaque 
characteristics scored semi-quantitatively (24). Semi-quantitative analysis of atherosclerotic 
plaque histology is well reproducible, both intra- and interobserver (25). Plaque classification 
was based on the size of the lipid core and cell population dominance (macrophages or smooth 
muscle cells [SMC]). Fibrous plaques were characterized by a small lipid core (<10%) with a 
dominance of SMCs whereas atheromatous plaques had an important lipid core (>40%) 
dominated by macrophages. For these human plaques, immunostaining studies were performed 
on vascular tissues (normal aorta, atherosclerotic plaques from carotid artery) obtained post-
mortem at autopsy. We used a TREM-1 goat polyclonal antibody on formalin-fixed-paraffin-
embedded tissues after antigen retrieval by heating in citrate buffer and ABC peroxidase 
technique as previously described (26). Polyclonal goat anti-P57 antibody was used as a 
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nonrelevant antibody for negative control procedure. Additionally, we stained macrophages 
(anti-CD68), SMCs (α-actin+ SMCs), CD3+ T cells, and neutrophils (myeloperoxidase). 
Total proteins were extracted from fresh human atherosclerotic carotid plaques after 
endarterectomy and TREM-1 protein levels were determined using Luminex xMAP Technology 
(Thermo Fisher Scientific, Inc., Waltham, Massachusetts). The plaques were obtained from the 
Athero-Express study, a longitudinal vascular biobank study that was approved by the Medical 
Ethics Committee of the University Medical Center Utrecht, the Netherlands, and in which 
participants provided written informed consent. 
Animals 
Experiments were conducted according to the guidelines formulated by the European 
Community for experimental animal use (L358-86/609EEC) and approved by the Ethical 
Committee of INSERM and the French Ministry of Agriculture (agreement A75-15-32). Trem-1-
/- mice (null for the Trem-1 gene) were generated by GenOway (Lyon, France) (23) and 
backcrossed for more than 10 generations into a C57BL/6J background. Ten-week old male 
C57BL/6J Ldlr-/- mice were subjected to medullar aplasia by lethal total body irradiation (9.5 
grays). The mice were repopulated with an intravenous injection of bone marrow cells isolated 
from femurs and tibias of sex-matched C57BL/6J Trem-1-/- mice or Trem-1+/+ littermates. After 
4 weeks of recovery, mice were fed a pro-atherogenic diet containing 15% fat, 1.25% 
cholesterol, and 0% cholate for 4, 8, or 14 weeks. Eight-week old male Apoe-/- mice were treated 
daily by intraperitoneal injection of the Trem-1 inhibitor LR12 (100 μg/day) or the peptide 
scramble during 4 weeks and were put either on a chow or high-fat diet (15% fat, 1.25% 
cholesterol). 
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LR12 (LQEEDAGEYGCM) and LR12-scramble (the inactive control peptide) were 
chemically synthesized as COOH terminally amidated peptides. The correct peptides were 
obtained with >99% yields and were homogeneous after preparative purification, as confirmed 
by mass spectrometry and analytic reversed-phase high-performance liquid chromatography. 
These peptides were free of endotoxin. Animals were blindly randomized to receive 5 mg/kg 
LR12 or LR12-scramble peptides intraperitoneally once a day for 28 days. We used the same 
dose of peptide as in studies on septic shock (21,22) and AMI (23). 
Extent and Composition of Atherosclerotic Lesions 
Plasma cholesterol was measured using a commercial cholesterol kit. Quantification of 
lesion size was performed as described previously (27). In brief, the basal half of the ventricles 
and ascending aorta were perfusion-fixed in situ with 4% paraformaldehyde. Afterwards, they 
were removed, transferred to a phosphate buffered saline (PBS)/30% sucrose solution, embedded 
in frozen optimal cutting temperature (OCT) and stored at −70° C. Serial 10 μm sections of the 
aortic sinus with valves (80 per mouse) were cut on a cryostat, as previously described (28). One 
of every 5 sections was kept for plaque size quantification after Oil Red O staining. Thus, 16 
sections, spanning an 800 μm stretch of the aortic root, were used to determine mean lesion area 
for each mouse. Oil Red O positive lipid contents were quantified by a blinded operator using 
HistoLab software (Microvisions Instruments, Paris France), which was also used for 
morphometric studies (29). En face quantification was used for atherosclerotic plaques along the 
thoraco-abdominal aorta. The aorta was flushed with PBS via the left ventricle and the aorta was 
removed from the root to the iliac bifurcation. Then, the aorta was fixed with 10% neutral-
buffered formalin. After a thorough washing, adventitial tissue was removed and the aorta 
opened longitudinally to expose the luminal surface. Afterward, the aorta was stained with oil 
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Red O for visualizing with the atherosclerotic lesions quantified, as just noted, by a blinded 
operator. Collagen was detected using Sirius red staining and necrotic core was quantified after 
Masson’s Trichrome staining. Macrophage presence was determined using specific antibodies, as 
previously described (29). At least 4 sections per mouse were examined for each immunostaining 
and appropriate negative controls were used. For immunostaining on mouse atherosclerotic 
plaques, we used antibodies against Trem-1 (Bs 4886R), macrophage + monocyte antibody 
(MOMA-2, specifically MAB1852), Ly6G (1A8), and CD3 (A0452). Terminal dUTP nick end-
labeling (TUNEL) staining was performed using histochemistry and fluorescent staining. Total 
proteins were extracted from human atherosclerotic plaque and TREM-1 protein level was 
quantified by Luminex. 
Cells were cultured in RPMI 1640 supplemented with Glutamax, 10% fetal calf serum 
(FCS), 0.02 mM β-mercaptoethanol, and antibiotics. For cytokine measurements, splenocytes 
were stimulated with lipopolysaccharide (LPS) (10 μg/ml) and interferon (Ifn)-γ (100 UI/ml) for 
24 or 48 hours. Il-10, Il-12 and Tnf-α production in the supernatants were measured using 
specific enzyme-linked immunoadsorbent assays (ELISA). 
Primary macrophages were derived from mouse bone marrow-derived cells (BMDM). 
Tibias and femurs of C57Bl6/J male mice were dissected and their marrow flushed out. Cells 
were grown for 7 days at 37° C in RPMI 1640 medium, 20% neonatal calf serum, and 20% 
macrophage–colony-stimulating factor (M-CSF)-rich L929-conditioned medium. To analyze 
oxidized LDL (oxLDL) uptake, BMDMs were exposed to human oxLDL (25 μg/ml) during 24 
and 48 h. Cells were washed, fixed, and stained using Red Oil. Foam cells were quantified 
blindly on 6 to 8 fields and the mean was recorded. To analyze macrophage phenotype, BMDMs 
were stimulated with LPS (10 μg/ml) and Ifn-γ (100 UI/ml) for 24 h. Il-10, Il-12, Il-1β, and Tnf-
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α production in the supernatant was measured using specific ELISAs. To analyze apoptosis 
susceptibility, macrophages were incubated with Tnf-α (10 ng/ml) and cycloheximide (10 
μmol/l) for 6 h or etoposide (50 μmol/l) for 12 h, or in an FCS-free medium. Apoptosis was 
determined by independent experiments using Annexin V (FITC) apoptosis detection kit with 7-
AAD (APC) (BD Biosciences, San Jose, California) according to the manufacturer's instructions. 
Human monocytes were isolated using anti-CD14 microbeads from healthy donors. Cells 
were cultured with M-CSF (50 ng/ml) during 7 days to induce mature macrophages. 
Nonclassical monocytes were labeled in vivo by retro-orbital intravenous injection of 1 
μm fluorescent microsphere diluted one-quarter in sterile PBS. Chimeric Ldlr-/- mice were 
sacrified 48 h later and cell labeling was checked by flow cytometry (30). Beads that reflect 
monocyte recruitment were quantified in 8 aortic sinus sections per mouse. Additional 
information regarding methods used is in the Online Appendix. 
Statistical Analysis 
Values are expressed as mean ± SE of the mean. Differences between values were 
examined using the nonparametric Mann-Whitney U test and were considered significant at p < 
0.05. 
Results  
To address the role of myeloid Trem-1 in the development of atherosclerosis, we 
performed bone marrow transplantation experiments using either Trem-1+/+ or Trem-1-/- bone 
marrow to repopulate lethally irradiated Ldlr-/- mice. In the chimeric Ldlr-/-/Trem-1+/+ control 
group, we confirmed that Trem-1 was expressed by circulating nonclassical monocytes (Figures 
1A and 1B) and also within the thoraco-abdominal aorta (Figure 1C). Trem-1 expression was 
almost abolished in circulating monocytes and atherosclerotic aorta of chimeric Ldlr-/-/Trem-1-/- 
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(Figures 1A through 1C). Leucocyte populations were not different between groups in the 
spleen, blood, or bone marrow except for a slight increase of Cd4+ T cells in chimeric Ldlr-/-
/Trem-1-/- mice (Online Figure 1). As shown in Figure 1, Trem-1 deficiency in the bone marrow 
was associated with a significant decrease in lesion development compared with controls; 42% 
decrease after 8 weeks of a fat diet (p < 0.01) (Figures 1D through 1F) and 60% decrease after 
14 weeks of a fat diet (p < 0.01) (Figures 1G and 1H). Additionally, Trem-1 deletion induced a 
less inflammatory plaque phenotype with significant reductions in both macrophage 
accumulation (Figures 1I through IK) and necrotic core size (Figures 1L through 1N) but no 
difference regarding collagen content (Online Figure 2). We observed no difference in body 
weights or serum cholesterol levels (Online Figure 2) between the 2 groups of mice. 
TREM-1 Deficiency Effects 
In order to gain insight into the mechanisms of reduction of macrophage and necrotic 
core content in Ldlr-/- mice reconstituted with Trem-1-/- bone marrow, we first evaluated 
apoptosis. In vitro, apoptosis susceptibility of Trem-1+/+ and Trem-1-/- macrophages was 
comparable between the 2 genetic backgrounds after serum deprivation or exposure to etoposide. 
However, apoptosis was slightly reduced in Trem-1-/- macrophages after stimulation with Tnf-
α/cycloheximide stimulation (Online Figure 3). In vivo, we found that Trem-1 deficiency led to 
a significant reduction in TUNEL+ cells in the atherosclerotic plaques (Figures 2A through 
2C). This observation might explain the decrease of necrotic core size but did not reconcile the 
apparent decrease in macrophages, suggesting that other mechanisms prevail. We then tested the 
possibility that Trem-1 controls monocyte infiltration into the lesions. We quantified monocyte 
recruitment to atherosclerotic plaque using a validated bead-labeling technique (30). After 4 
weeks of fat diet, chimeric Ldlr-/- mice were intravenously injected with fluorescent beads and 
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sacrificed 48 h later. We confirmed the reduction of atherosclerosis development at early stages 
(data not shown) in Ldlr-/-/Trem-1-/- mice and observed a significant reduction of the recruitment 
of Trem-1-/- bead-positive monocytes within the lesions in comparison with Trem-1+/+ 
monocytes (Figures 2D through 2F). In parallel, we evaluated the peritoneal recruitment of 
nonclassical monocytes following a septic and a nonseptic injury. After intraperitoneal injection 
of LPS or thioglycollate, nonclassical monocyte recruitment was significantly reduced within the 
peritoneal cavity in Trem-1 deficient animals (Online Figure 4). These findings showed that 
Trem-1-/- circulating monocytes have reduced ability to migrate into inflammatory sites and 
colonize plaques, corroborating a previously identified role of Trem-1 in promoting neutrophil 
migration during acute inflammation (31). 
Because Trem-1 is reported to amplify cytokine production, particularly in response to 
Tlr agonists (32,33), we next investigated the immuno-inflammatory response in chimeric Ldlr-/- 
mice. LPS/Ifn-γ-stimulated splenocytes showed a deviation toward an anti-inflammatory profile 
in Ldlr-/-/Trem-1-/- chimeric mice with a reduction of Tnf-α/Il-10 and Il-12p70/Il-10 ratios 
(Figure 2G). The expression of Il-10, Il-12p70, Il1β, and Il-6 messenger ribonucleic acids 
(mRNA) was also significantly reduced in the spleens of Ldlr-/-/Trem-1-/- mice (Figures 2H 
through 2K). Furthermore, Trem-1-/- BMDMs were less prone to polarize toward a pro-
inflammatory phenotype after LPS/Ifn-γ, as they produced less Tnf-α, Il-12p70, and Il-1β and 
more Il-10 compared to Trem-1+/+ BMDMs (Figure 2L). However, expressions of Nos2 and 
Arg1 in the abdominal aorta (as markers of M1 and M2 macrophages, respectively) were not 
different between chimeric Ldlr-/-/Trem-1-/- and Ldlr-/-/Trem-1+/+ mice after 6 weeks of fat diet 
(Figures 2M and 2N). Finally, we investigated macrophage metabolism including mitochondrial 
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respiration and glycolysis; those functions were very similar between Trem-1+/+ and Trem-1-/- 
macrophages (Online Figure 5). 
We speculated that the marked reduction of Oil Red O+ lesions in Ldlr-/-/Trem-1-/- mice 
could be due, at least in part, to reduced foam cell formation. To explore this hypothesis, we 
performed in vitro experiments to examine the uptake of oxLDL by BMDMs and their ability to 
accumulate intracellular lipids. Interestingly, foam cell formation was significantly reduced in 
Trem-1-/- cultured macrophages compared to Trem-1+/+ macrophages after 24 and 48 h of 
incubation with oxLDL (Figures 3A through 3F). In contrast, phagocytosis of apoptotic cells or 
Zymosan beads was not altered by Trem-1 deficiency (Online Figure 6), suggesting a selective 
role in lipid uptake. We found no difference in Sr-b1, Abca1, or Abcg1 mRNA expression and 
only a slight and delayed reduction of Sr-a mRNA expression in Trem-1-/- cells (Figures 3G 
through 3I; data not shown). However, we observed a marked reduction of Cd36 mRNA 
expression in Trem-1-/- cultured macrophages at baseline and after stimulation with oxLDL 
(Figures 3G through 3I). A reduction of Cd36 protein was further confirmed by flow cytometry 
(Figures 3J and 3K). We also quantified Cd36 protein expression in the plaques of chimeric 
Ldlr-/- mice and found a profound decrease of Cd36 staining in the absence of bone marrow-
derived Trem-1 (Figures 3L though 3N). To start addressing the mechanisms of Trem-1-
dependent upregulation of Cd36, we investigated signaling pathways downstream of Trem-1 that 
may control Cd36 expression. BMDMs co-incubated with oxLDL were treated with different 
pharmacological inhibitors and Cd36 expression was quantified 16 h later using flow cytometry. 
Pharmacological blockade of Erk1/2 (PD98059) or Nf-κb (PDTC) had no effect on Cd36 
expression (data not shown). However, incubation with Wortmaninn significantly reduced 
oxLDL-induced Cd36 expression on Trem-1+/+ BMDMs down to levels seen in Trem-1-/- 
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BMDMs (Figure 3O), suggesting a role for phosphatidylinositol 3 kinase (PI3K) activation in 
TREM-1-dependent upregulation of Cd36 following exposure to oxLDL. 
Genetic Invalidation of TREM-1 
We next addressed the role of TREM-1 in Apoe-/- mice. We found an elevated expression 
of Trem-1 mRNA expression in the aorta of Apoe-/- mice on fat diet and, to a lesser extent, in 
Apoe-/- mice on chow diet, compared to healthy C57Bl6 aortas, which showed no expression of 
Trem-1 (Online Figure 7A). Trem-1 expression levels within the aorta significantly correlated 
with plaque size (r = 0.71; p = 0.0003) and macrophage infiltration (r = 0.87; p < 0.0001) in the 
aortic sinus (Online Figure 7B). Immunostaining confirmed that TREM-1 was expressed in 
atherosclerotic lesions of Apoe-/- mice and co-localized mainly with MOMA+ macrophages 
(Figure 4A). We also detected a few TREM-1+ Ly6G+ neutrophils in atherosclerotic lesions at 
that stage of lesion development (Figure 4B). To investigate the role of TREM-1 in this model, 
we generated Apoe-/-/Trem-1-/- mice. Trem-1 deficiency in myeloid population was confirmed by 
flow cytometry (Figures 4C and 4D) and by immunostaining in atherosclerotic plaques 
(Figures 4E and 4F). Experiments in chimeric Ldlr-/- mice suggested that TREM-1 modulates 
nonclassical recruitment into atherosclerotic lesions. We therefore explored the expression of 
Cx3 chemokine receptor 1 (Cx3cr1), a major chemokine receptor of non-classical monocytes 
(34). Using flow cytometry on Apoe-/- mice, we found that Cx3cr1 expression was restricted to 
TREM-1+ nonclassical monocytes (Figures 4G through 4I). After 2 weeks of fat diet, Cx3cr1 
expression (mean fluorescence intensity [MFI]) on TREM-1+ nonclassical monocytes was 14-
fold higher than on TREM-1- nonclassical monocytes. Then we compared Cx3cr1 expression on 
nonclassical monocytes of Apoe-/-/Trem-1+/+ and Apoe-/-/Trem-1-/- mice. As shown in Figures 4J 
and 4K, we found a strong reduction of Cx3cr1 expression (MFI) on Apoe-/-/Trem-1-/- 
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nonclassical monocytes in comparison to control Apoe-/-/Trem-1+/+ nonclassical monocytes. 
Cx3cr1 expression (MFI) on classical monocytes was not different between Apoe-/-/Trem-1+/+ 
and Apoe-/-/Trem-1-/- mice (data not shown). Finally, we analyzed the phenotype of mature 
peritoneal macrophages isolated from Apoe-/-/Trem-1+/+ and Apoe-/-/Trem-1-/- mice by 
quantitative polymerase chain reaction after LPS/Ifn-γ stimulation. We found a significant 
increase of Il-10 mRNA expression and a significant decrease of Il-12p70 and Arginase 1 by 
Apoe-/-/Trem-1-/- macrophages (Figures 4L through 4P). 
There was no significant difference in plasma cholesterol levels between Apoe-/-/Trem-
1+/+ and Apoe-/-/Trem-1-/- groups (Figure 5A). At 10 weeks of age, animals were put on a fat diet 
for 6 weeks to accelerate plaque formation. Apoe-/-/Trem-1-/- showed a significant reduction of 
atherosclerotic lesion formation in the aortic sinus (-41%; p < 0.05) (Figures 5B through 5D) 
and along the thoraco-abdominal aorta (-56%; p = 0.005) (Figures 5E through 5G). 
Additionally, Trem-1 deletion in Apoe-/- background induced a switch toward a less 
inflammatory plaque phenotype with significant reductions in macrophage accumulation 
(Figures 5H through 5K), necrotic core size (Figures 5L though 5O), and TUNEL+ area (only 
absolute area) (Figures 5P through 5S). We did not observe any difference in T cell 
accumulation (Online Figure 8A) and plaque collagen content (Online Figure 8B) between the 
2 groups of mice. 
Pharmacologic Blockade of TREM-1 
To evaluate a new therapeutic approach in atherosclerosis, we used a dodecapeptide 
LR12, a validated inhibitor of TREM-1 activation (21,23). LR12 reduced oxLDL uptake by 
BMDMs (Figures 6A through 6C) and down-regulated Cd36 expression (Figure 6D). Both 
results were confirmed in human monocyte-derived macrophages (Online Figure 9). Using 
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Apoe-/- peritoneal macrophages, we confirmed that LR12 treatment reduced Cd36 mRNA 
(Figure 6E) and induced a deviation of the immune response toward an anti-inflammatory 
profile with an increase of Il-10 and a reduction of Il-12p70 and Tnf-α production following 
LPS/Ifn-γ stimulation (Figure 6F). Using human monocytes, LR12 also down-regulated IL-12, 
TNF-α, and CD36 mRNA expression (Online Figure 10). Next, we investigated the 
consequences of TREM-1 pharmacological inhibition on monocyte trafficking. Apoe-/- mice fed 
a fat diet and treated with daily intraperitoneal injections of scramble or LR12 peptide during 2 
weeks were intravenously injected with fluorescent beads 48 h before sacrifice. We observed a 
significant reduction of the recruitment of bead-positive monocytes within the lesions of LR12-
treated Apoe-/- mice (Figures 6G through 6I). 
To evaluate the effects of TREM-1 inhibition on atherosclerosis, Apoe-/- male mice were 
treated during 4 weeks with daily intraperitoneal injections of LR12 or a scramble control 
peptide. LR12 treatment had no effect on cholesterolemia (Online Figures 11A and 11B) but 
significantly reduced atherosclerosis growth on a chow diet (56,600 ± 22,300 μm2 vs. 98,900 ± 
30,900 μm2; p < 0.05) (Figures 6J through 6L), and on a high-fat diet both in the aortic sinus 
(103,300 ± 21 100 μm2 vs. 148,700 ± 15,200 μm2; p < 0.05) (Figures 6M through 6O) and the 
thoraco-abdominal aorta (6.0 ± 3.0% vs. 2.5 ± 0.9%; p < 0.05) (Figures 6p through 6R). 
TREM-1 pharmacological inhibition also reduced macrophage accumulation (Figures 6S 
through 6U) and TUNEL+ cells/debris (Online Figure 11C) in the lesions, but had no effect on 
T cell infiltration (Online Figure 11D) or collagen content (Online Figure 11E). To investigate 
the role of neutrophils in the atheroprotection induced by TREM-1 blockage, neutrophil-depleted 
Apoe-/- mice were treated with daily intraperitoneal injections of scramble or LR12 peptide for 4 
weeks. Administration of anti-Ly6G depleting antibody every 3 days led to 70% depletion of 
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circulating neutrophils. As shown in Online Figure 12, the atheroprotection induced by 
pharmacological inhibition of TREM-1 was preserved in neutrophil-depleted animals. 
TREM-1 EXPRESSED IN ATHEROSCLEROTIC HUMAN LESIONS. To evaluate the 
clinical relevance of our results, we examined TREM-1 expression in human atherosclerotic 
plaques from carotid arteries. TREM-1 was not detected in normal aorta (Figures 7A and 7B). 
However, TREM-1 was expressed in fatty streak lesions (Figures 7C and 7D) and in advanced 
atherosclerotic plaques (Figure 7E and 7F), in areas surrounding the necrotic core (Figure 6G). 
Immunohistochemistry showed that TREM-1 staining localized to the membrane of giant lipid-
laden foam cells (Figure 7H). Fluorescent staining confirmed that TREM-1 expression was 
mostly confined to CD68+ intimal macrophages (Figure 7I) and a few neutrophils (Online 
Figure 13A), but was not detected in α-actin+ SMCs (Figure 7J) or CD3+ T cells (Online 
Figure 13B). We quantified TREM-1 protein levels in human plaque extracts obtained after 
endarterectomy (Online Figure 14), and found TREM-1 expression was significantly higher in 
atheromatous lesions compared to fibrous lesions (p = 0.002) (Figure 7K).  
Discussion 
Using 3 complementary approaches, we found that TREM-1 deficiency/inhibition 
significantly reduced atherosclerosis growth in mice and induced a less inflammatory plaque 
phenotype characterized by reduced macrophage infiltration and necrotic core size. It is 
interesting to note that TREM-1 deletion or blockade was associated with significant and 
profound (up to 60%) reduction of the development of both early and advanced atherosclerosis 
and the protective effect was observed throughout the aorta (aortic sinus, ascending and 
descending aorta). This contrasted with the relatively modest (and mostly nonsignificant) impact 
of many other innate immune pathways on lesion development in this model, including deletion 
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of Cd36 (12), Tlr2/Tlr4 (10), Il-1 (35), or Tnfr signaling (36) in bone marrow-derived cells. We 
believe that the marked nonredundant effect of TREM-1 on atherosclerosis is due to the major 
role of this innate receptor in coordinating several complementary pro-atherogenic processes. 
Here, we identified a few atheroprotective mechanisms induced by TREM-1 deletion/blockade: 
reduction of nonclassical monocyte infiltration in plaques; reduction of macrophage pro-
inflammatory response; and reduced foam cell formation (Central Illustration). We have also 
shown that TREM-1 was expressed in advanced human atherosclerotic lesions, mostly close to 
cholesterol-rich and necrotic-rich areas and its expression was significantly higher in 
atheromatous lesions. 
TREM-1 is highly conserved during evolution (37) and mainly expressed by bone 
marrow-derived leukocytes (15). In our study, TREM-1 was highly expressed in circulating 
neutrophils and Gr1lo, but not Gr1hi, monocytes. Deletion of TREM-1 in bone marrow-derived 
cells did not significantly alter leukocyte number in blood but limited Gr1lo monocyte 
recruitment into developing atherosclerotic lesions. TREM-1 was mainly expressed by 
macrophages in atherosclerotic lesions and colocalized with a few infiltrating neutrophils. We 
believe that the atheroprotection induced by TREM-1 invalidation/blockage was not mediated by 
neutrophil modulation. First, TREM-1 inhibition reduced both atherosclerosis formation and 
progression whereas neutrophils are mostly involved in the initiation of atherosclerosis in 
experimental models (38). Second, the reduction of atherosclerosis induced with TREM-1 
pharmacological inhibition was preserved despite marked (70%) neutrophil depletion. However, 
we cannot exclude a small contribution of neutrophils to the pro-atherogenic role of TREM-1. 
It is plausible that reduced recruitment of nonclassical monocytes has contributed to the 
reduction of lesion development after TREM-1 deletion/blockade. We identified a sub-
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population of nonclassical monocytes that co-express TREM-1 and Cx3cr1. Interestingly, the 
reduction of Cx3cr1 expression on this monocyte subset in Trem-1-deficient animals suggested 
an important role for TREM-1 in the regulation of Cx3cr1 expression under conditions of high-
fat feeding. However, downstream signaling pathways remain unknown. Another potential 
important consequence of Cx3cr1 modulation by TREM-1 could be reduced interaction of 
TREM-1-deficient macrophages with intimal smooth muscle cells that express high levels of 
Cxc3cr1 ligand, Cx3cl1. Collectively, our data were consistent with the role of Cx3cl1/Cxc3cr1 
signaling in experimental atherosclerosis (39-42). 
Whether differentiating from Gr1lo or Gr1hi monocytes, most macrophages upregulate 
TREM-1 expression upon activation. Our study extended previous findings by highlighting the 
amplifier effect of TREM-1 engagement on the inflammatory response of macrophages in the 
context of atherosclerosis. Genetic invalidation of Trem-1 in BMDMs modulated the systemic 
innate inflammatory response as illustrated by the reduction of Tnf-α/Il-10 and Il-12p70/Il-10 
ratios in the spleens of Ldlr-/-/Trem-1-/- mice. Trem-1-/- macrophages displayed a more anti-
inflammatory phenotype with less production of pro-atherogenic Il-12, Il-1β, and Tnf-α (3,8) 
and increased production of anti-atherogenic Il-10 (43,44). A similar anti-inflammatory 
phenotype was observed after pharmacological inhibition of TREM-1 in both human monocytes 
and mouse macrophages. The regulation of Il-1β and Tnf-α production by TREM-1 has 
previously been reported in vitro using LPS-stimulated (human and animal) neutrophils, LPS-
stimulated monocytes (45), and cultured foam cells (46). Similar regulation of innate immune 
responses by TREM-1 were described in other aseptic contexts, as during experimental colitis 
(47,48) or, more recently, by our group during AMI (23). Furthermore, in a model of ureteral 
obstruction–induced nephritis, Trem-1 deficiency reduced M1 macrophage polarization within 
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the kidney, as illustrated by a decrease of Nos2 and an increase of Arg1 expression (49). We 
observed no major differences in those 2 markers in the aorta of Ldlr-/-/Trem-1+/+ and Ldlr-/-
/Trem-1-/- mice. The discrepancy could be related to the disease setting (different types of sterile 
inflammation, acute versus chronic context) or to differences in local environmental cues, which 
are known to impact macrophage phenotype (50). 
Necrotic core size is another major predictor of plaque vulnerability (51). The formation 
and progression of the necrotic core is influenced by a variety of pro-atherogenic processes, 
including lipid accumulation, inflammatory cell activation, and the rates of apoptotic cell death 
and efferocytosis within the lesions. The TREM-1/DAP12 signaling pathway involves 
extracellular signal-regulated kinase and PI3K/AKT, 2 cascades regulating cell survival (52,53). 
However, the effect of Trem-1 stimulation on monocyte/macrophage survival is not well-
defined. So far, available studies have reported contradictory results suggesting that the role of 
TREM-1 on cell survival depends on the cell type and the experimental conditions. For example, 
Radsak et al. found that TREM-1 engagement on neutrophils had no effect on apoptosis 
susceptibility, but promoted apoptosis in the presence of TLR ligands (54). In contrast, Cai et al. 
observed that TREM-1 overexpression on human monocytes promoted cell survival in the 
presence of staurosporine (55). In our study, we used 3 different apoptotic challenges and 
observed a slight reduction of apoptosis in Trem-1-/- BMDM only after Tnf-α/cycloheximide 
stimulation. In vivo, we observed a reduction of TUNEL+ area in atherosclerotic plaques of Ldlr-
/-/Trem-1-/- chimeric mice, Apoe-/-Trem-1-/- mice, and LR12-treated Apoe-/-mice compared to their 
respective controls, consistent with the reduced susceptibility of Trem-1-/- macrophages to 
apoptosis. However, the reduction of plaque apoptosis and necrotic core in the absence of 
TREM-1 could also be secondary to reduced macrophage accumulation and activation. 
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Foam cell formation is a major determinant of plaque development and progression. 
Given the drastic reduction of the area of aortic Oil Red O staining in the absence of TREM-1, 
we investigated the role of TREM-1 in macrophage foam cell formation and found a marked 
reduction of oxLDL uptake and lipid accumulation in Trem-1-/- macrophages. Among the major 
receptors that govern lipid body formation in macrophages (i.e., Sr-a, Sr-b1, Cd36, Abca1, 
Abcg1), TREM-1 deletion selectively altered the expression of Cd36 both at the gene and cell 
surface protein expression levels, and both in vitro and within atherosclerotic plaque 
macrophages in vivo. We found that signaling through PI3K, which is activated downstream of 
TREM-1 (33,56) was required for TREM-1-dependent upregulation of Cd36 in response to 
oxLDL, consistent with the role of PI3K activation in the induction of Cd36 (57,58). The 
profound reduction of atherosclerosis observed in chimeric Ldlr-/-/Trem-1-/- mice was 
independent of the genetic background (observed under Apoe-/- and Ldlr-/- background), and the 
high-fat diet (observed under chow-fed Apoe-/- mice and high-fat diet-fed Ldlr-/- mice). Thus, it is 
difficult to entirely attribute this marked impact on atherosclerosis to the reduction of CD36 
expression, given the variable impact of CD36 on the development of atherosclerosis in mice, 
which depends on the Apoe/Ldlr background and the presence or absence of cholesterol-enriched 
high-fat diet (13,59-61). Previous studies have shown that interactions between Cd36 and several 
Tlrs were required for optimal induction of sterile inflammation (and macrophage apoptosis) by 
atherogenic lipids (10,11,62). However, in vivo evidence for an additive or synergistic effect of 
combined blockade of Cd36 and Tlr pathways was still lacking. TREM-1 signaling is a major 
amplifier of Tlr-dependent responses (63), and we demonstrated here that it is also critical for 
both basal and oxLDL-induced Cd36 expression. Therefore, we believe that the combined 
reduction of inflammatory signaling and Cd36 expression after TREM-1 deletion promoted a 
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synergistic effect and was ultimately responsible for the marked reduction in inflammatory foam 
cell formation and plaque development. Our data supported the combinatorial concept of 
synergistic Cd36-Tlr signaling and showed that blockade of a single cell surface receptor, here 
TREM-1, might be equivalent to a double-hit approach, simultaneously impacting 2 major and 
interdependent pro-atherogenic processes. 
Despite the crucial role of the immune response in atherosclerosis development (1,3), 
therapeutic strategies targeting innate immune pathways have mostly failed (4,64), although 
some continue clinical testing (65). We believe that a double-hit approach through TREM-
1blockade, as is the case with the use of the inhibitory LR12 dodecapeptide, may provide 
extended benefit and will be worthy of clinical testing. The relevance of such an approach is 
further supported by our clinical findings of increased levels of TREM-1 in atheromatous human 
atherosclerotic lesions and the very significant association between high circulating levels of 
soluble TREM-1 and major adverse cardiovascular events in patients with AMI (23). A first 
clinical trial to assess the safety, tolerability, and pharmacokinetics of TREM-1 blockade using 
LR12 peptide in healthy volunteers is ongoing. We speculate that acute coronary disease patients 
represent the population of choice that could benefit from LR12 treatment because TREM-1 
inhibition would prevent myeloid cell recruitment to the ischemic heart (23) and the 
atherosclerotic plaques, limiting deleterious post-ischemic cardiac remodeling, the acceleration 
of atherosclerosis after ischemic injury (66) and the recurrence of atherothrombotic events (67). 
Study Limitations 
In this study, we found that TREM-1 inhibition protected against atherosclerosis 
development through several anti-inflammatory and anti-atherogenic mechanisms. However, we 
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did not specifically modulate these pathways (i.e., Cx3cr1 or Cd36) to decipher their direct roles 
and relative importance in mediating TREM-1 pro-atherogenic effects. 
Conclusions 
Altogether, our studies identified TREM-1 as a crucial player in the development and 
complications of atherosclerosis, both in experimental models and in humans. This was achieved 
through the unique role of TREM-1 in connecting and coordinating signaling through several                              
pattern recognition receptors (e.g., CD36 and TLR4), which led to the activation of synergistic 
pro-atherogenic pathways, namely innate inflammatory activation of macrophages and foam cell 





COMPETENCY IN MEDICAL KNOWLEDGE: TREM-1 is an important factor in the 
progression of atherosclerosis in both experimental and clinical models. 
TRANSLATIONAL OUTLOOK: Further studies are needed to assess the efficacy of 




1. Libby P, Lichtman AH, Hansson GK. Immune effector mechanisms implicated in 
atherosclerosis: from mice to humans. Immunity 2013;38:1092-104. 
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 
2005;352:1685-95. 
3. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. 
Physiol Rev 2006;86:515-81. 
4. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 
2011;145:341-55. 
5. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat 
Med 2011;17:1410-22. 
6. Potteaux S, Ait-Oufella H, Mallat Z. Role of splenic monocytes in atherosclerosis. Curr 
Opin Lipidol 2015;26:457-63. 
7. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74. 
8. Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Recent advances on the role of cytokines in 
atherosclerosis. Arterioscler Thromb Vasc Biol 2011;31:969-79. 
9. Robbins CS, Hilgendorf I, Weber GF, et al. Local proliferation dominates lesional 
macrophage accumulation in atherosclerosis. Nat Med 2013;19:1166-72. 
10. Seimon TA, Nadolski MJ, Liao X, et al. Atherogenic lipids and lipoproteins trigger 
CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell 
Metab 2010;12:467-82. 
11. Stewart CR, Stuart LM, Wilkinson K, et al. CD36 ligands promote sterile inflammation 
through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 2010;11:155-61. 
25 
12. Brown PM, Kennedy DJ, Morton RE, Febbraio M. CD36/SR-B2-TLR2 Dependent 
Pathways Enhance Porphyromonas gingivalis Mediated Atherosclerosis in the Ldlr KO Mouse 
Model. PLoS One 2015;10:e0125126. 
13. Moore KJ, Freeman MW. Scavenger receptors in atherosclerosis: beyond lipid uptake. 
Arterioscler Thromb Vasc Biol 2006;26:1702-11. 
14. Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be 
triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 
2000;164:4991-5. 
15. Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and 
is a crucial mediator of septic shock. Nature 2001;410:1103-7. 
16. Ford JW, McVicar DW. TREM and TREM-like receptors in inflammation and disease. 
Curr Opin Immunol 2009;21:38-46. 
17. Klesney-Tait J, Keck K, Li X, et al. Transepithelial migration of neutrophils into the lung 
requires TREM-1. J Clin Invest 2013;123:138-49. 
18. Yasuda T, Takeyama Y, Ueda T, et al. Increased levels of soluble triggering receptor 
expressed on myeloid cells-1 in patients with acute pancreatitis. Crit Care Med 2008;36:2048-53. 
19. Kuai J, Gregory B, Hill A, et al. TREM-1 expression is increased in the synovium of 
rheumatoid arthritis patients and induces the expression of pro-inflammatory cytokines. 
Rheumatology (Oxford) 2009;48:1352-8. 
20. Derive M, Bouazza Y, Sennoun N, et al. Soluble TREM-like transcript-1 regulates 
leukocyte activation and controls microbial sepsis. J Immunol 2012;188:5585-92. 
21. Derive M, Boufenzer A, Bouazza Y, et al. Effects of a TREM-like transcript 1-derived 
peptide during hypodynamic septic shock in pigs. Shock 2013;39:176-82. 
26 
22. Derive M, Boufenzer A, Gibot S. Attenuation of responses to endotoxin by the triggering 
receptor expressed on myeloid cells-1 inhibitor LR12 in nonhuman primate. Anesthesiology 
2014;120:935-42. 
23. Boufenzer A, Lemarie J, Simon T, et al. TREM-1 Mediates Inflammatory Injury and 
Cardiac Remodeling Following Myocardial Infarction. Circ Res 2015;116:1772-82. 
24. Verhoeven BA, Velema E, Schoneveld AH, et al. Athero-express: differential 
atherosclerotic plaque expression of mRNA and protein in relation to cardiovascular events and 
patient characteristics. Rationale and design. Eur J Epidemiol 2004;19:1127-33. 
25. Hellings WE, Pasterkamp G, Vollebregt A, et al. Intraobserver and interobserver 
variability and spatial differences in histologic examination of carotid endarterectomy 
specimens. J Vasc Surg 2007;46:1147-54. 
26. Bariety J, Mandet C, Hill GS, Bruneval P. Parietal podocytes in normal human glomeruli. 
J Am Soc Nephrol 2006;17:2770-80. 
27. Ait-Oufella H, Herbin O, Bouaziz JD, et al. B cell depletion reduces the development of 
atherosclerosis in mice. J Exp Med 2010;207:1579-87. 
28. Daugherty A, Whitman SC. Quantification of atherosclerosis in mice. Methods Mol Biol 
2003;209:293-309. 
29. Mallat Z, Gojova A, Brun V, et al. Induction of a regulatory T cell type 1 response 
reduces the development of atherosclerosis in apolipoprotein E-knockout mice. Circulation 
2003;108:1232-7. 
30. Potteaux S, Gautier EL, Hutchison SB, et al. Suppressed monocyte recruitment drives 
macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression. J 
Clin Invest 2011;121:2025-36. 
27 
31. Klesney-Tait J, Keck K, Li X, et al. Transepithelial migration of neutrophils into the lung 
requires TREM-1. J Clin Invest 2012. 
32. Zanzinger K, Schellack C, Nausch N, Cerwenka A. Regulation of triggering receptor 
expressed on myeloid cells 1 expression on mouse inflammatory monocytes. Immunology 
2009;128:185-95. 
33. Dower K, Ellis DK, Saraf K, Jelinsky SA, Lin LL. Innate immune responses to TREM-1 
activation: overlap, divergence, and positive and negative cross-talk with bacterial 
lipopolysaccharide. J Immunol 2008;180:3520-34. 
34. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets 
with distinct migratory properties. Immunity 2003;19:71-82. 
35. Freigang S, Ampenberger F, Weiss A, et al. Fatty acid-induced mitochondrial uncoupling 
elicits inflammasome-independent IL-1alpha and sterile vascular inflammation in 
atherosclerosis. Nat Immunol 2013;14:1045-53. 
36. Xanthoulea S, Gijbels MJ, van der Made I, et al. P55 tumour necrosis factor receptor in 
bone marrow-derived cells promotes atherosclerosis development in low-density lipoprotein 
receptor knock-out mice. Cardiovasc Res 2008;80:309-18. 
37. Klesney-Tait J, Turnbull IR, Colonna M. The TREM receptor family and signal 
integration. Nat Immunol 2006;7:1266-73. 
38. Drechsler M, Megens RT, van Zandvoort M, Weber C, Soehnlein O. Hyperlipidemia-
triggered neutrophilia promotes early atherosclerosis. Circulation 2010;122:1837-45. 
39. Combadiere C, Potteaux S, Gao JL, et al. Decreased atherosclerotic lesion formation in 
CX3CR1/apolipoprotein E double knockout mice. Circulation 2003;107:1009-16. 
28 
40. Lesnik P, Haskell CA, Charo IF. Decreased atherosclerosis in CX3CR1-/- mice reveals a 
role for fractalkine in atherogenesis. J Clin Invest 2003;111:333-40. 
41. Combadiere C, Potteaux S, Rodero M, et al. Combined inhibition of CCL2, CX3CR1 and 
CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in 
hypercholesterolemic mice. Circulation 2008;117:1649-57. 
42. Cheng C, Tempel D, van Haperen R, et al. Shear stress-induced changes in 
atherosclerotic plaque composition are modulated by chemokines. J Clin Invest 2007;117:616-
26. 
43. Mallat Z, Besnard S, Duriez M, et al. Protective role of interleukin-10 in atherosclerosis. 
Circ Res 1999;85:e17-24. 
44. Potteaux S, Deleuze V, Merval R, et al. In vivo electrotransfer of interleukin-10 cDNA 
prevents endothelial upregulation of activated NF-kappaB and adhesion molecules following an 
atherogenic diet. Eur Cytokine Netw 2006;17:13-8. 
45. Gibot S, Kolopp-Sarda MN, Bene MC, et al. A soluble form of the triggering receptor 
expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis. J Exp Med 
2004;200:1419-26. 
46. Wang YS, Li XJ, Zhao WO. TREM-1 is a positive regulator of TNF-alpha and IL-8 
production in U937 foam cells. Bosn J Basic Med Sci 2012;12:94-101. 
47. Schenk M, Bouchon A, Seibold F, Mueller C. TREM-1--expressing intestinal 
macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory 
bowel diseases. J Clin Invest 2007;117:3097-106. 
48. Weber B, Schuster S, Zysset D, et al. TREM-1 deficiency can attenuate disease severity 
without affecting pathogen clearance. PLoS Pathog 2014;10:e1003900. 
29 
49. Lo TH, Tseng KY, Tsao WS, et al. TREM-1 regulates macrophage polarization in 
ureteral obstruction. Kidney Int 2014;86:1174-86. 
50. Gosselin D, Link VM, Romanoski CE, et al. Environment drives selection and function 
of enhancers controlling tissue-specific macrophage identities. Cell 2014;159:1327-40. 
51. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am 
Coll Cardiol 2006;47:C13-8. 
52. Colonna M. TREMs in the immune system and beyond. Nat Rev Immunol 2003;3:445-
53. 
53. Tessarz AS, Cerwenka A. The TREM-1/DAP12 pathway. Immunol Lett 2008;116:111-6. 
54. Radsak MP, Salih HR, Rammensee HG, Schild H. Triggering receptor expressed on 
myeloid cells-1 in neutrophil inflammatory responses: differential regulation of activation and 
survival. J Immunol 2004;172:4956-63. 
55. Cai M, Chen Q, Chen C, et al. Activation of triggering receptor expressed on myeloid 
cells-1 protects monocyte from apoptosis through regulation of myeloid cell leukemia-1. 
Anesthesiology 2013;118:1140-9. 
56. Gomez-Pina V, Martinez E, Fernandez-Ruiz I, et al. Role of MMPs in orchestrating 
inflammatory response in human monocytes via a TREM-1-PI3K-NF-kappaB pathway. J 
Leukoc Biol 2012;91:933-45. 
57. Lin CS, Lin FY, Ho LJ, et al. PKCdelta signalling regulates SR-A and CD36 expression 
and foam cell formation. Cardiovasc Res 2012;95:346-55. 
58. Mwaikambo BR, Yang C, Chemtob S, Hardy P. Hypoxia up-regulates CD36 expression 
and function via hypoxia-inducible factor-1- and phosphatidylinositol 3-kinase-dependent 
mechanisms. J Biol Chem 2009;284:26695-707. 
30 
59. Febbraio M, Podrez EA, Smith JD, et al. Targeted disruption of the class B scavenger 
receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 
2000;105:1049-56. 
60. Moore KJ, Kunjathoor VV, Koehn SL, et al. Loss of receptor-mediated lipid uptake via 
scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic 
mice. J Clin Invest 2005;115:2192-201. 
61. Kennedy DJ, Kuchibhotla SD, Guy E, et al. Dietary cholesterol plays a role in CD36-
mediated atherogenesis in LDLR-knockout mice. Arterioscler Thromb Vasc Biol 2009;29:1481-
7. 
62. Sheedy FJ, Grebe A, Rayner KJ, et al. CD36 coordinates NLRP3 inflammasome 
activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in 
sterile inflammation. Nat Immunol 2013;14:812-20. 
63. Arts RJ, Joosten LA, van der Meer JW, Netea MG. TREM-1: intracellular signaling 
pathways and interaction with pattern recognition receptors. J Leukoc Biol 2013;93:209-15. 
64. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to 
atherosclerosis: lessons from mouse models. Nat Rev Immunol 2008;8:802-15. 
65. Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1beta inhibition with 
canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a 
phase IIb randomized, placebo-controlled trial. Circulation 2012;126:2739-48. 
66. Dutta P, Courties G, Wei Y, et al. Myocardial infarction accelerates atherosclerosis. 
Nature 2012;487:325-9. 
31 
67. Keeley EC, Velez CA, O'Neill WW, Safian RD. Long-term clinical outcome and 
predictors of major adverse cardiac events after percutaneous interventions on saphenous vein 




Central Illustration: Proatherogenic Effects of TREM-1 Engagement. Triggering receptors 
expressed on myeloid cells (TREM-1) activation orchestrates monocyte recruitment, macrophage 
pro-inflammatory responses, and foam cell formation. Pharmacological blockade of TREM-1 
signaling using LR12 peptide may constitute an attractive novel and double-hit approach for the 
treatment of atherosclerosis. CD = cluster of differentiation; Cx3cr1 = Cx3 chemokine receptor 
1; LDL = low-density lipoprotein. 
 
Figure 1 Trem-1 Deficiency in Reduces Atherosclerosis. In low-density lipoprotein receptor 
(Ldlr)-/- mice, triggering receptors expressed on myeloid cells (Trem-1) deficiency in myeloid 
cells reduced development of atherosclerosis and induced a stable plaque phenotype. As seen in 
flow cytometry on blood leucocytes gated on cluster of differentiation (CD)11b+CD115high 
monocytes, TREM-1 was expressed by nonclassical Gr1low monocytes in the control (Ldlr-/-
/Trem-1+/+ ) group (A) but was absent in Ldlr-/-/Trem-1-/-  mice (B).(C) Using quantitative 
polymerase chain reaction on aortas of chimeric Ldlr-/- mice after 6 weeks of fat diet, Trem-1 
messenger ribonucleic acid (mRNA) was detected in the control group but its expression was 
almost abolished in the Ldlr-/-/Trem-1-/- group. Representative photomicrographs of controls (D) 
and Trem-1-deficient mice (E) and quantitative analysis (F) of atherosclerotic lesions of 
chimeric Ldlr-/- mice after 8 weeks of fat diet. Quantitative analysis of atherosclerotic lesions of 
chimeric Ldlr-/- mice after 14 weeks of fat diet in the (G) left aortic sinus and (H) thoraco-
abdominal aorta. E, representative photomicrographs of controls (I) and Trem-1-deficient mice 
(J) and quantitative analysis (K) of macrophage accumulation (macrophage + monocyte 
antibody [MOMA] staining) in atherosclerotic lesions of chimeric Ldlr-/- mice. Representative 
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photomicrographs of controls (L) and Trem-1-deficient mice (M) and quantitative analysis (N) 
of acellular area (Masson’s Trichrome) of chimeric Ldlr-/- mice. *p < 0.05; **p < 0.01; ***p < 
0.001 Scale bar = 200 μm. 
 
Figure 2: Monocyte Infiltration in Atherosclerotic Plaques. TREM-1 deficiency reduced 
monocyte migration into atherosclerotic lesions and limited macrophage inflammatory response. 
Representative photomicrographs of controls (A) and Trem-1-deficient mice (B) and quantitative 
analysis (C) of terminal dUTP nick end-labeling (TUNEL)+ apoptotic area (Red/Brown, arrows) 
within atherosclerotic lesions of chimeric Ldlr-/- mice after 8 weeks of fat diet. Representative 
photomicrographs of controls (D) and Trem-1-deficient mice (E) and quantitative analysis (F) of 
beads within atherosclerotic lesions of chimeric Ldlr-/- mice after 4 weeks of fat diet. (G) 
Cytokine production by lipopolysaccharide (LPS)/interferon (Ifn)-γ-stimulated splenocytes 
isolated from chimeric Ldlr-/- mice. Quantification of interleukin (Il) (H) Il-10, (I) Il-12p70, (J) 
Il-1β, and (K) Il-6 mRNA expression in the spleens of chimeric Ldlr-/- mice. (L) Cytokine 
production by LPS/Ifnγ-stimulated bone marrow-derived macrophages (BMDM) isolated from 
Ldlr-/- chimeric mice, 6 weeks after transplantation. Quantification of (M) iNOS and (N) 
Arginase 1 mRNA expression in abdominal aortas from chimeric Ldlr-/- mice.  *p < 0.05; **p < 
0.01; ***p < 0.001 Scale bar = 200 μm. Data are expressed as median and percentiles (5th-95th). 
Abbreviations as in Figure 1. 
 
Figure 3: Pro-inflammatory Macrophage Responses and Lipid Uptake. Trem-1 promoted 
phosphatidylinositol 3 kinase (PI3K)-dependent expression of Cd36 in macrophages and induced 
foam cell formation. Quantitative analysis (A) and representative photomicrographs of controls 
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(B) and Trem-1-deficient mice (C) at 24 h and at 48 h (D-F) after incubation of BMDMs from 
Trem-1+/+ and Trem-1-/- mice with oxidized low-density lipoprotein (oxLDL). Quantification of 
(G) Sr-a, (H) Sr-b1, and (I) Cd36 mRNAs in BMDMs from Trem-1+/+ and Trem-1-/- mice at 
baseline and after stimulation with oxLDL.  (J) Flow cytometry quantification of Cd36 
expression by BMDMs from Trem-1+/+ and Trem-1-/- mice at baseline and after stimulation with 
oxLDL. (K) Histograms depict specific MFI of Trem-1+/+ and Trem-1-/- macrophages exposed to 
oxLDL and stained with an antibody to Cd36. Quantification (L) and representative 
photomicrographs of Cd36 expression in plaques from chimeric (M) Ldlr-/-/Trem-1+/+ and (N) 
Ldlr-/-/Trem-1-/- mice. (O) Effects of PI3K inhibition on Cd36 expression by BMDMs (flow 
cytometry). * P<0.05. ** P<0.01. Data are expressed as median and percentiles (5th-95th). MFI = 
mean fluorescence intensity; other abbreviations as in Figures 1 and 2. 
 
Figure 4: TREM-1 in Atherosclerotic Plaque and Expression of Cx3cr1. (A) TREM-1 
(green) is expressed in atherosclerotic plaques of apoliprotein E-deficient (Apoe-/-) tissue and 
colocalizes (yellow) with MOMA+ macrophages (red). (B) Few Ly6G+ neutrophils (red) were 
detected in plaque of Apoe-/- mice and colocalized (yellow) with TREM-1. (C) Flow cytometry 
analysis confirmed that TREM-1 was expressed on circulating CD11b+ myeloid cells from (C) 
Apoe-/-/Trem-1+/+ but not (D) Apoe-/-/Trem-1-/- mice. TREM-1 (green) is expressed in (E) Apoe-/-
/Trem-1+/+ but was not detected in (F) Apoe-/-/Trem-1-/- plaques. (G-I) TREM-1+ Cd11b+Ly6G-
LyClow nonclassical monocytes express Cx3 chemokine receptor 1 (Cx3cr1). (J and K) 
Comparison of Cx3Cr1 expression by Cd11b+Ly6G-LyClow nonclassical monocytes of Apoe-/-
/Trem-1+/+ and Apoe-/-/Trem-1-/- mice. Quantification of (L) Il-10, (M) Il-12, (N) Nos2, (O) 
Arginase 1, and (P) Ym1 mRNAs expression by peritoneal macrophages of Apoe-/-/Trem-1+/+ and 
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Apoe-/-/Trem-1-/- mice. *p < 0.05; **p < 0.01. Scale bar = 100 μm. Data are expressed as median 
and percentiles (5th-95th). 
 
Figure 5: Genetic Invalidation of Trem-1: Atherosclerosis Reduction. After 6 weeks of a fat 
diet, various parameters differed in mouse groups: (A) plasma cholesterol levels; atherosclerotic 
lesions in (B-D) the aortic sinus and (E-G) in the thoraco-abdominal aorta. Variations are seen in 
(H-K) macrophage accumulation, (L-O) acellular area (after Masson’s Trichrome), and (P-S) 
TUNEL+ in ApoE-/-/Trem-1+/+ and ApoE-/-/Trem-1-/- mice. *p < 0.05; **p < 0.01. Scale bar = 
200 μm (C and D) and 100 μm (J, K, N, O, R, S). Abbreviations as in Figures 1, 2, 4, and 5. 
 
Figure 6: Monocyte/macrophage Function Modulations. Pharmacological blockade of 
TREM-1, though injections of scramble or LR12 peptide, modulated monocyte and macrophage 
functions reducing atherosclerosis development as seen via (A-C) foam cell formation and (D) 
Cd36 expression after co-incubation of BMDMs with oxLDL and peptide during 24 h; (E) Cd36 
mRNA expression in peritoneal macrophages from ApoE-/- mice treated with daily peptide 
injections during 3 days prior to cell isolation; (F) cytokine production by LPS/Ifn-γ-stimulated 
peritoneal macrophages;  (G-I) beads within atherosclerotic lesions of treated ApoE-/- mice after 
2 weeks of fat diet; atherosclerotic lesion size after 4 weeks of (J-L) chow diet or fat diet as seen 
in the (M-O) aortic sinus and (P-R) thoracic aorta; and (S-U) macrophage infiltration in 
atherosclerotic lesions  after 4 weeks of fat diet. *p < 0.05. Scale bar = 200 μm. Data are 
expressed as median and percentiles (5th-95th). Abbreviations as in Figures 1, 2, and 3. 
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Figure 7: TREM-1 protein expression in human atherosclerotic plaques. TREM-1 is not 
expressed in normal aorta (A, B) but is expressed in fatty streak lesions of the aorta (C, D) and in 
advanced carotid artery plaques (E, F) mainly around the necrotic core (G). TREM-1 was 
strongly expressed by cells that engulf lipids and cholesterol crystals and on the membrane of 
giant lipid-laden foam cells (H). Fluorescent staining confirmed that TREM-1 was expressed by 
CD68+ macrophages (I) but not by α-actin+ smooth muscle cells (J). TREM-1 expression was 
significantly higher in atheromatous lesions in comparison with fibrous plaques (K). Magnitude: 











From the Methods Section 
FLOW CYTOMETRY AND PCR. Blood samples were collected at the sacrifice for 
analysis of leukocyte subsets. Myeloid cells were identified as CD11b+. Monocytes were 
identified as CD11b+Ly6G- or CD11b+CD115high. Among them, classical monocytes were 
Gr1high (or Ly6Chigh) and non-classical monocytes were Gr1low (or Ly6Clow). Neutrophils 
were identified as CD11b+CD115low or CD11b+Ly6G+. CD4+ and CD8+ lymphocyte 
subsets were also analyzed. Stainings included the following antibodies: PerCP-conjugated 
anti-CD45, FITC-conjugated anti-CD11b, PE-conjugated anti-CD115, Anti-Gr1 (Ly6C and 
G)-PERCP-Cy5, anti-Cx3cr1-PERCP-Cy7, anti-F4/80-PE, anti-CD4-V-450 anti-CD3ε-APC, 
anti-B220-V-500, anti-CD8a-AF-700, anti-MHCII-FITC, and anti-CD19 AF-700. 
Forward scatter (FSC) and side scatter (SSC) were used to gate live cells excluding red 
blood cells, debris, and cell aggregates in total blood cells and splenocytes. Cells were 
acquired using a flow cytometer and analyzed with FlowJo software (FloJo, LLC, Ashland, 
Oregon). 
Quantitative real-time polymerase chain reaction (PCR) was performed, after Trizol 
ribonucleic acid (RNA) extraction and real-time PCR, on an ABI Prism 7700 Sequence 
Detection System (Thermo Fisher Scientific, Inc.) in duplicate for each sample. Expression of 
all genes has been normalized using 3 housekeeping genes (Gapdh, Hprt and Ppia). Relative 
expression was calculated using the 2-delta-delta computed tomography (CT) method 
followed by geometric average, as recommended (1,2). The following primer sequences were 
used: Il-10 (F:5’ –AAG TGA TGC CCC AGG CA- 3’; R:5’ –TCT CAC CCA GGG AAT 
TCA AA- 3’), Trem-1 (F:5’- TGC GGT TGT TCC CTC TCC TGG TCT TG-3’; R:5’ - TGT 
GAA ATA GAC ACC GCT GAA GGT CAC T-3’); Nos2 (F:5’- TTG GGC CTG GTA CGG 
GCA TTG-3’; R:5’ - CAA GCT CAT GCG GCC TCC TTT-3’), Arg1 (F:5’- TCT GCA TGG 
GCA ACC TGT GTC-3’; R:5’ –TGC AGG GAG TCA CCC AGG AGA-3’), Ym1 (F :5’- 
2 
GAA GCC CTC CTA AGG ACA AAC-3’ ; R :5’-GCA GCC TTG GAA TGT CTT TCT-3’), 
Tnf (F:5’- GAT GGG GGG CTT CCA GAA CT-3’; R:5’ –CGT GGG CTA CAG GCT TGT 
CAC-3’), Il-6 (F:5’- AAA GAC AAA GCC AGA GTC CTT CAG AGA GAT-3’; R:5’– GGT 
CTT GGT CCT TAG CCA CTC CTT CTG T-3’), Il-12a  (F:5’- TCA CAC GGG ACC AAA 
CCA GCA CAT -T-3’; R:5’ –TGT GGG GGC AGG CAG CTC CCT CTT -3’), Il-1b ( F:5’- 
GAA GAG CCC ATC CTC TGT GA – 3’; R:5’- GGG TGT GCC GTC TTT CAT TA – 3’), 
Sra (F:5’- TGG ATG CAA TCT CCA AGT CCT- 3’; R:(5’: ACG TGC CTT GTT CTT CTT 
T -3’) , Srb (F:5’- GCT CCG GAA CAA GGC AAA TA – 3’; R: 5’- GGC CAG ATC CAC 
GAC AGT 6 – 3’), Cd36 (F:5’- TGG CCA AGC TAT TGC GAC ATG ATT -A-3’; R:5’ –
CGG GGA TTC CTT TAA GGT CGA TTT-C-3’), Abcg1 (F:5’- GGG GCC CTG GTC GAA 
GAA GAA AGC A-3’; R:5’ –TCC TTT CTT CTT CCA CCA GGG CCC C-3’), and Abca1 
(F:5’- TAA ATT CCA CAT CTC ATC TCC CGA CCC AG-3’; R:5’ –CTG GGT CGG GAG 




1. Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for 
publication of quantitative real-time PCR experiments. Clin Chem 2009;55:611-22. 
2. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time 




Online Figure Legends 
Online Figure 1. No difference of blood leukocyte populations between chimeric Ldlr-/- 
/Trem-1+/+ and chimeric Ldlr-/- /Trem-1-/- mice. Flow cytometry characterization of leucocyte 
subsets in chimeric Ldlr-/- mice in the blood (A) and the bone marrow (B). *P<0.05 
 
Online Figure 2. No difference of cholesterolemia and collagen content between chimeric 
Ldlr-/- /Trem-1+/+ and chimeric Ldlr-/- /Trem-1-/- mice. Cholesterolemia from Ldlr-/- chimeric 
mice after 8 weeks (A) and 14 weeks of high fat diet (B). Representative photomicrographs 
and quantitative analysis of collagen content within atherosclerotic lesions of chimeric Ldlr-/- 
mice after 8 weeks of fat diet (Sirius red staining) (C). 
 
Online Figure 3. Trem-1 deficiency did not alter macrophage apoptosis susceptibility. 
Bone marrow-derived macrophages isolated from Trem-1 +/+ (opened circles) or Trem-1 -/- 
mice (filled circles) were challenged in vitro during 24 hours and apoptosis was evaluated by 
flow cytometry. Apoptotic cells were defined as annexin Vpos 7-AADneg cells. * P<0.05, NS, 
non significant. 
 
Online Figure 4. Trem-1 deficiency impaired non-classical monocyte recruitment into 
inflammatory sites. Decrease of non-classical monocyte recruitment within the peritoneal 
cavity following septic or non-septic injury. Twelve-week old male Apoe-/-Trem-1+/+ and 
Apoe-/-Trem-1-/- received LPS (2.5mg/kg) (B) or Thioglycollate (C) intraperitoneally and were 
sacrified 3 hours (LPS) or 12 hours (Thioglycollate) later. Peritoneal cells were harvested and 
analysed by flow cytometry (A). Neutrophils were identified as CD45+CD11b+Ly6G+, 
classical monocytes were CD45+CD11b+Ly6G-Ly6Chigh and non-classical monocytes were 
CD45+CD11b+Ly6G-Ly6Clow. **, P<0.01 
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Online Figure 5. Trem-1 deficiency did not impair macrophage metabolism Exploration 
of BMDMs metabolism including mitochondrial respiration and glycolysis (Seahorse XF 
Technology). Extracellular acidification rates (ECAR, left) and real-time oxygen consumption 
rates (OCR, right) of Trem-1+/+ and Trem-1-/- macrophages were determined using the 
Seahorse Extracellular Flux (XFe96) analyzer (Seahorse Bioscience, Paris, France). 
Macrophages were cultured into XFe96 well culture plates and incubated at 37°C in a 5% 
CO2 humidified atmosphere. At day 7, macrophages were stimulated with LPS (1 μg/ml) 
during 24 hours. Then cells were washed in XF assay media (or for OCR measurement, XF 
assay media supplemented with 10 mM glucose, 1 mM Pyruvate, 2 mM L-glutamine and 
adjusted at 7.4 pH), which were pre-warmed to 37°C. Macrophages cells were then 
maintained in 140 μL/well of XF assay media at 37°C, in a non-CO2 incubator for 1 h. 
During incubation, we loaded 16 μL of 10 mM glucose, 1 μM oligomycin, 50 mM 2-
deoxyglucose (for ECAR measurement) and 1 μM oligomycin, 1 μM FCCP, 0.5 μM rotenone, 
0.5 μM antimycin A (for OCR measurement), in XF assay media into the injection ports in 
the XFe96 sensor cartridge. Data set was analyzed by XFe96 software and GraphPad Prism 
software, using one-way ANOVA calculations. All experiments were performed in triplicate, 
three times. 
 
Online Figure 6. Trem-1 deficiency did not impair efferocytosis. A, phagocytosis of 
CFSE-labeled apoptotic thymocytes by bone marrow-derived macrophages (gated on 
CD11b+F4/80+ cells). Flow cytometry after 1 hour of co-incubation (N=6/group). 
Phagocytosis of Zymosan beads by bone marrow-derived macrophages. Quantification using 
Imagestream technology after 1 hour of co-incubation (N=4/group). 
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Online Figure 7. Trem-1 is expressed in mouse atherosclerotic plaques. A, Trem-1 mRNA 
expression is not detectable in aorta of C57Bl6 mice but is expressed in atherosclerotic aorta 
of apoE-/- mice fed a chow (CD) or fat diet (FD). B, in apoE-/- mice, Trem-1 mRNA expression 
in thoracic aorta was strongly correlated to macrophage infiltration in atherosclerotic plaques 
in the aortic sinus. Expression of Trem-1 has been normalised using three housekeeping genes 
(Gapdh, Hprt and Ppia). Relative expression was calculated using the 2-delta-delta CT 
method followed by geometric average. N=6-7/group. * **P<0.001. 
 
Online Figure 8. No difference of T cell infiltration and collagen content in plaques from 
apoE-/- Trem+/+ and apoE-/-Trem-/- mice. Representative photomicrographs and quantitative 
analysis of CD3+ T cell infiltration (fluorescent staining, A) and collagen content (Sirius Red, 
B) within atherosclerotic lesions of apoE-/- Trem+/+ and apoE-/-Trem-/- mice after 6 weeks of 
fat diet. N=7/group. Scale bar 100 μm. 
 
Online Figure 9. LR-12 peptide limited lipid uptake by human macrophages and 
reduces CD36 expression. A, B. Human peripheral blood mononuclear cells were isolated 
from the whole blood of healthy volunteers using CD14 microbeads isolation kit (StemcellTM). 
After 7 days of incubation with M-CSF (50ng/mL), the cells were used as human monocyte-
derived macrophages. Cells were incubated with oxLDL (25μg/mL) and treated with 
Scramble or LR-12 peptide (50 ng/mL) during 24H and 48 hours. Foam cells were quantified 
after red oil staining. C, Human monocytes (Monomac6) were stimulated for 6 hours by 
oxLDL (25 μg/mL) in presence of Scramble or LR12 peptide (50 ng/mL). CD36 expression 
was analyzed by flow cytometry * P<0.05, ** P<0.01. 
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Online Figure 10. LR-12 down regulates IL-12, TNF-α and CD36 mRNA expression by 
human monocytes. Isolated blood human monocytes were stimulated in vitro with LPS 
(1μg/ml) and co-incubated with Scramble or LR-12 peptide during 6 hours. Expression of all 
genes has been normalised using three housekeeping genes (Gapdh, Hprt and Ppia). Relative 
expression was calculated using the 2-delta-delta CT method followed by geometric average. 
N=3/group. * P<0.05. 
 
Online Figure 11. LR-12 peptide reduced apoptosis within atherosclerotic plaques. 
Cholesterolemia from apoE-/- mice treated with daily intraperitoneal injection of LR-12 or 
scramble peptide during 4 weeks on a chow (A) and a high fat diet (B). Representative 
photomicrographs and quantitative analysis of TUNEL+ area (Brown, C), CD3+ T cell 
infiltration (D) and collagen content (E) within atherosclerotic lesions of apoE-/- mice treated 
with daily injection of LR-12 or scramble peptide during 4 weeks on a high fat diet. ** 
P<0.01. scale bar 100 μm.  
 
Online Figure 12. Atheroprotection induced by LR-12 peptide was preserved in 
neutrophil-depleted apoE-/- mice. A, intraperitoneal injection of Anti-Ly6G depleting 
antibody (1A8) or Isotype in apoE-/- mice lead to a 65% reduction of circulating neutrophils at 
day 2. B, experimental protocol of neutrophil depletion in Scramble or LR-12-treated apoE-/- 
mice fed a fat diet. C, Blood neutrophil count at the sacrifice. D, Representative 
photomicrographs and quantification of atherosclerotic plaque size (aortic sinus) after 4 
weeks of fat diet. * P<0.05, ** P<0.01.  
 
Online Figure 13. TREM-1 expression by neutrophils in human atherosclerotic plaques. 
Immunohistochemistry. A, Few Myeloperoxydase+ neutrophils (Brown, arrow) are detected 
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in atherosclerotic plaques and they colocalize with TREM-1 (Red). B, CD3+ T cells (Brown, 
arrow) do not colocalize with TREM-1 (Red).  
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